Filing Pursuant to Rule 424(b)(2)
                                            Registration Statement No. 333-33774

                               AMENDMENT NO. 1 TO
                           PROSPECTUS SUPPLEMENT NO. 8

                       TO PROSPECTUS DATED APRIL 19, 2000,
              PROSPECTUS SUPPLEMENT NO. 1 DATED NOVEMBER 16, 2000,
              PROSPECTUS SUPPLEMENT NO. 2 DATED JULY 19, 2001, AND
                PROSPECTUS SUPPLEMENT NO. 3 DATED AUGUST 20, 2001
              PROSPECTUS SUPPLEMENT NO. 4 DATED SEPTEMBER 28, 2001
               PROSPECTUS SUPPLEMENT NO. 5 DATED DECEMBER 17, 2001
               PROSPECTUS SUPPLEMENT NO. 6 DATED DECEMBER 17, 2001
               PROSPECTUS SUPPLEMENT NO. 7 DATED DECEMBER 18, 2001

                                3,333,333 SHARES

                          ADVANCED VIRAL RESEARCH CORP.

                                  COMMON STOCK

         You should read this prospectus supplement no. 8 along with the
accompanying prospectus and prospectus supplements nos. 1 through 7. These
documents contain information you should consider when making your investment
decision. You should rely only on the information contained or incorporated by
reference in this prospectus supplement no. 8 and the accompanying prospectus
and prospectus supplements nos. 1 through 7. We have not authorized anyone else
to provide you with different or additional information.

         This prospectus supplement no. 8 and the accompanying prospectus and
prospectus supplements nos. 1 through 7 do not constitute an offer to sell or a
solicitation of an offer to buy any securities other than the common stock
offered hereby. This prospectus supplement no. 8 and the accompanying prospectus
and prospectus supplements nos. 1 through 7 do not constitute an offer to sell
or a solicitation of an offer to buy our common stock in any circumstances in
which an offer or solicitation is unlawful.

         Information in this prospectus supplement no. 8 and the accompanying
prospectus and prospectus supplements nos. 1 through 7 may change after the date
on the front of the applicable document. You should not interpret the delivery
of this prospectus supplement no. 8 or the accompanying prospectus and
prospectus supplements nos. 1 through 7 or the sale of the common stock as an
indication that there has been no change in our affairs since that date.

         Our principal executive offices are located at 200 Corporate Boulevard
South, Yonkers, New York 10701. Our telephone number is (914) 376-7383.

                               ------------------

         Investing in our common stock involves a high degree of risk. See "RISK
FACTORS" beginning on page 3 of the prospectus.

                               ------------------

         Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.

                               ------------------

        The date of this prospectus supplement no. 8 is February 7, 2002





                                 USE OF PROCEEDS

         We will use the net proceeds of this offering of our common stock as
described in the prospectus. See "Use of Proceeds" beginning on page 7 of the
prospectus.

                                HIGH RISK FACTORS

         As of the date of this prospectus, we do not have sufficient funds to
sustain our operations, nor do we have funds to pay our debts as they become
due. During the next 12 months, we expect to incur significant expenditures
relating to operating expenses and expenses relating to regulatory filings and
clinical trials for Product R. We currently do not have cash availability to
meet our anticipated expenditures.

         We are currently seeking additional financing. If none of our
outstanding options and warrants are exercised, and we obtain no other
additional financing, in order for us to achieve the level of operations
contemplated by management, management anticipates that we will have to limit
intentions to expand operations beyond current levels.

         We anticipate that we will be required to sell additional securities to
obtain the funds necessary to further our research and development activities.
We are currently seeking debt financing, licensing agreements, joint ventures
and other sources of financing, but the likelihood of obtaining such financing
on favorable terms is uncertain. Management is not certain whether, at present,
debt or equity financing will be readily obtainable on favorable terms. Because
of the large uncertainties involved in the FDA approval process for commercial
drug use on humans, it is possible that we may never be able to sell Product R
commercially. Please see page 5 of the prospectus for a discussion of other risk
factors.



                                      S-2

                              PLAN OF DISTRIBUTION

         Pursuant to this prospectus supplement no. 8, we are offering 3,333,333
shares of our common stock to Roseworth Group Limited, a British Virgin Islands
corporation (the "Purchaser"). We have entered into a Stock Purchase Agreement
dated as of February 7, 2002 with the Purchaser pursuant to which we will issue
and sell to the Purchaser 3,333,333 shares of our common stock at a negotiated
price of $0.15 per share, for a total purchase price of $500,000. The Purchaser
is a wholly-owned subsidiary of Creon Management, S.A., a British Virgin Islands
corporation whose wholly-owned subsidiary, Cambois Finance, Ltd., also a British
Virgin Islands corporation, purchased 6,666,667 shares of our common stock at a
negotiated price of $0.15 per share pursuant to a Stock Purchase Agreement dated
September 28, 2001. Other than the foregoing and a Stock Purchase Agreement
dated November 16, 2000 whereby the Purchaser purchased 4,960,317 shares of our
common stock at a negotiated price of $0.3024 per share, there has been no
material relationship between the Purchaser and Advanced Viral Research Corp. in
the past three years.

         The Purchaser is an "underwriter" within the meaning of the Securities
Act of 1933 in connection with its sale of the shares purchased from us as
described in this prospectus supplement no. 8. Broker-dealers or other persons
acting on the behalf of parties that participate in the distribution of the
shares may also be deemed to be underwriters. Any commissions or profits they
receive on the resale of the shares may be deemed to be underwriting discounts
and commissions under the Securities Act.

         During the time the Purchaser is engaged in distributing shares covered
by this prospectus supplement no. 8 and accompanying prospectus and prospectus
supplements nos. 1 through 7, the Purchaser may be subject to, among other
regulations, Regulation M under the Securities Exchange Act of 1934. With
certain exceptions, to the extent the Purchaser is subject to Regulation M, it
may not engage in any stabilization activity in connection with our securities,
must furnish each broker who offers shares of common stock covered by this
prospectus supplement no. 8 and accompanying prospectus and prospectus
supplements nos. 1 through 7 with the number of copies of this prospectus
supplement no. 8 and accompanying prospectus and prospectus supplements nos. 1
through 7 which are required by each broker, and may not bid for or purchase any
of our securities or attempt to induce any person to purchase any of our
securities other than as permitted under the Exchange Act.

                           MARKET FOR OUR COMMON STOCK

         Our common stock is traded on the National Association of Securities
Dealers, Inc.'s OTC Bulletin Board under the symbol "ADVR." On February 6, 2002
the high and low bid prices for our common stock on the Bulletin Board were
$0.205 and $0.185 respectively. As of February 5, 2002, we had 403,296,863
shares of common stock outstanding.

                       WHERE YOU CAN FIND MORE INFORMATION

         The SEC allows us to "incorporate by reference" information that we
file with them, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
an important part of this prospectus supplement no. 8 and the accompanying
prospectus and prospectus supplements nos. 1 through 7. We incorporate the
documents indicated on page 9 of our prospectus.




                                      S-3